Related Experiment Video
Updated: Apr 5, 2026

09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
12.2K
Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study
Orlando Galego1, Ana Gouveia2, Sónia Batista2
1Coimbra Hospital and University Centre, Department of Neuroradiology, Coimbra, Portugal orlando.galego@gmail.com.
The Neuroradiology Journal
|August 7, 2015
Summary
Physical disability in primary progressive multiple sclerosis (PPMS) is not directly linked to brain atrophy. However, grey matter volume loss correlates with lesion load, suggesting inflammation contributes to neurodegeneration.
Area of Science:
- Neurology
- Neuroimaging
- Neurodegeneration
Background:
- Primary progressive multiple sclerosis (PPMS) is characterized by progressive neurodegeneration.
- Grey matter atrophy is observed in PPMS, but its link to clinical disability is unclear.
Purpose of the Study:
- To investigate the relationship between regional brain atrophy and physical disability in PPMS patients.
Main Methods:
- Nineteen PPMS patients underwent neurological evaluation and brain MRI.
- Volumetric analysis of brain structures was performed using FreeSurfer.
- Physical disability was assessed using the Expanded Disability Status Scale (EDSS).
Main Results:
- No significant correlation was found between EDSS score or disease duration and grey or white matter volumes.
- Lesion load was negatively correlated with cortical and subcortical grey matter volumes.
- No correlation was observed between lesion load and total white matter volume.
Conclusions:
- Physical disability in PPMS is not directly associated with brain volume loss.
- Grey matter atrophy in PPMS correlates with lesion load, suggesting inflammatory lesions may drive neurodegeneration.
Related Concept Videos
Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Neuroplasticity
2.5K
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
2.5K

